China’s NMPA releases proposal for modified “Hatch Waxman” following patent law reform

Published date21 September 2020
Subject MatterPharmaceutical Industry,Intellectual Property Protection,Pharmaceutical Patents,Comment Period,Hatch-Waxman,Generic Drugs,Regulatory Standards,Regulatory Agenda,China,Prescription Drugs
AuthorXin Tao,Philip Katz
Law FirmHogan Lovells

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT